Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Disrupted Micronuclei Cited as Potential Non-Small-Cell Lung Cancer Biomarkers

By BiotechDaily International staff writers
Posted on 16 Jul 2013
Cancer researchers have found that collapse of the nuclear membrane that surrounds micronuclei—bits of the genome that become detached during cell replication—may allow these damaged segments of DNA to reenter the cell's genetic material with possible cancer-causing consequences.

Investigators at the Salk Institute for Biological Sciences (La Jolla, CA, USA) worked with cultures of non-small-cell lung cancer (NSCLC) cells. They reported in the July 3, 2013, issue of the journal Cell that micronuclei, which were sometimes generated when these cells replicated, had reduced functioning compared to primary nuclei in the same cell, although the two compartments appeared to be structurally comparable. Over 60% of micronuclei were found to undergo an irreversible loss of compartmentalization during interphase due to collapse of their nuclear envelope.

The disruption of the micronuclei, which was induced by defects in nuclear lamina assembly, drastically reduced nuclear functions and had the potential to trigger massive DNA damage. Disruption of micronuclei was associated with chromatin compaction and invasion of endoplasmic reticulum (ER) tubules into the chromatin.

Disrupted micronuclei were detected in both major subtypes of NSCLC, suggesting that this feature could be a useful objective biomarker for genomic instability in solid tumors.

"Our study shows that more than 60% of micronuclei undergo catastrophic dysfunction in solid tumors such as NSCLC," said senior author Dr. Martin Hetzer, professor of molecular and cell biology at the Salk Institute for Biological Sciences. "We identified disrupted micronuclei in two major subtypes of human non-small-cell lung cancer, which suggests that they could be a valuable tool for cancer diagnosis."

Related Links:
Salk Institute for Biological Sciences



Channels

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.